Gynecologic oncology research and practice最新文献

{"title":"Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.","authors":"Brett Miles, Howard P Safran, Bradley J Monk","doi":"10.1186/s40661-017-0047-8","DOIUrl":"10.1186/s40661-017-0047-8","url":null,"abstract":"<p><p>Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacterial vector <i>Listeria monocytogenes</i> (<i>Lm</i>) activates innate and adaptive immune responses and is expected to offer immunologic advantages. Axalimogene filolisbac (AXAL or ADXS11-001) is a novel immunotherapeutic based on the live, irreversibly attenuated <i>Lm</i> fused to the nonhemolytic fragment of listeriolysin O (<i>Lm</i>-LLO) and secretes the <i>Lm</i>-LLO-HPV E7 fusion protein targeting HPV-positive tumors. Herein are reported the development and recent results of various clinical trials in patients with HPV-associated cervical, head and neck, and anal cancers.</p>","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 ","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2017-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35183143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.","authors":"Brett A Miles,&nbsp;Bradley J Monk,&nbsp;Howard P Safran","doi":"10.1186/s40661-017-0046-9","DOIUrl":"https://doi.org/10.1186/s40661-017-0046-9","url":null,"abstract":"<p><p>Immune responses to the facultative intracellular bacterium <i>Listeria monocytogenes</i> (<i>Lm</i>) are robust and well characterized. Utilized for decades as a model of host-disease immunology, <i>Lm</i> is well suited for use as an immunotherapeutic bacterial vector for the delivery of foreign antigen. Genetic modification of <i>Lm</i> has been undertaken to create an attenuated organism that is deficient in its master transcriptional regulator, protein-related factor A, and incorporates a truncated, nonhemolytic version of the listeriolysin O (LLO) molecule to ensure its adjuvant properties while also preventing escape of the live organism from the phagolysosome. Delivery of a vaccine construct (<i>Lm</i>-LLO-E7; axalimogene filolisbac [AXAL] or ADXS11-001) in which the modified LLO molecule is fused with the E7 oncoprotein of human papillomavirus type 16 (HPV-16) consistently stimulates strong innate and E7 antigen-specific adaptive immune responses, resulting in reduction of tumor burden in animal cancer models. In the clinical setting, AXAL has shown early promise in phase I/II trials of women with cervical cancer, and several more trials are currently underway to assess the efficacy and safety of this antitumor vaccine in patients with HPV-positive head and neck and anal cancers.</p>","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2017-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0046-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35067190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana.","authors":"Dorcas Obiri-Yeboah,&nbsp;Yaw Adu-Sarkodie,&nbsp;Florencia Djigma,&nbsp;Kafui Akakpo,&nbsp;Ebenezer Aniakwa-Bonsu,&nbsp;Daniel Amoako-Sakyi,&nbsp;Jacques Simpore,&nbsp;Philippe Mayaud","doi":"10.1186/s40661-017-0044-y","DOIUrl":"https://doi.org/10.1186/s40661-017-0044-y","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1186/s40661-017-0041-1.].</p>","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2017-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0044-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34864042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?","authors":"Bradley J Monk, Warner K Huh, Julie Ann Rosenberg, Ira Jacobs","doi":"10.1186/s40661-017-0045-x","DOIUrl":"10.1186/s40661-017-0045-x","url":null,"abstract":"<p><strong>Objective: </strong>Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules that are intended to be highly similar to, and treat the same condition(s) as, an existing licensed or approved (reference) biologic, with no clinically meaningful differences in purity, potency and safety. This article summarizes the role of bevacizumab in the treatment paradigm of ovarian and cervical cancer. We also discuss the potential role of biosimilars to bevacizumab, which may offer more affordable options in the future treatment of gynecologic cancers.</p><p><strong>Methods: </strong>Literature searches of PubMed and ClinicalTrials.gov databases were conducted. Regulatory and individual pharmaceutical company web pages were also reviewed. Search terms included \"biosimilar\" and \"bevacizumab,\" and these were used to identify information regarding biosimilar development, reporting results of biosimilar studies or biosimilars in development.</p><p><strong>Results: </strong>At present, four bevacizumab biosimilar candidates are undergoing comparative clinical assessment, with the potential to increase access and offer efficiencies across healthcare systems.</p><p><strong>Conclusions: </strong>It is anticipated that biologics such as bevacizumab will continue to play a key role in the treatment of an array of gynecologic cancers. Biosimilars to bevacizumab are currently in development and have the potential to increase access to medicines in a variety of settings, including gynecologic cancers.</p>","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2017-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0045-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34858162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.","authors":"Radoslav Chekerov,&nbsp;Philipp Harter,&nbsp;Stefan Fuxius,&nbsp;Lars Christian Hanker,&nbsp;Linn Woelber,&nbsp;Lothar Müller,&nbsp;Peter Klare,&nbsp;Wolfgang Abenhardt,&nbsp;Yoana Nedkova,&nbsp;Isil Yalcinkaya,&nbsp;Georg Heinrich,&nbsp;Harald Sommer,&nbsp;Sven Mahner,&nbsp;Pauline Wimberger,&nbsp;Dominique Koensgen-Mustea,&nbsp;Rolf Richter,&nbsp;Gülten Oskay-Oezcelik,&nbsp;Jalid Sehouli","doi":"10.1186/s40661-017-0040-2","DOIUrl":"https://doi.org/10.1186/s40661-017-0040-2","url":null,"abstract":"<p><strong>Background: </strong>Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (≥65 years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as secondary endpoints.</p><p><strong>Methods: </strong>Patients with ROC had the free choice between treosulfan i.v. (7000 mg/m² d1, q29d) or p.o. (600 mg/m² daily d1-28, q57d). Only indecisive participants were randomized.</p><p><strong>Results: </strong>Overall 123 patients with 2^nd to 5^th recurrence were registered and 119 received at least one cycle of chemotherapy. 85.7% preferred treosulfan i.v. and 14.3% oral, where only three patients were randomized. Main reasons for i.v. preference associated with individual expectations of lower rate of gastrointestinal disorders, higher activity and tolerability of treatment. Median of applied chemotherapies was three (range 1-12 cycles), with most common grade 3/4 toxicities thrombopenia (18.7%), leukopenia (15.7%), ascites (7.6%), bowel obstruction (6.7%), and abdominal pain (4.2%). Median time until progression/overall survival was 5.2/7.8 months (i.v.), and 5.6/10.4 months (p.o.), respectively, without significant differences in efficacy.</p><p><strong>Conclusions: </strong>Elderly patients with recurrent ovarian cancer asked and demonstrated active participation in the decision-making process of their oncological treatment and favoured predominantly the i.v. application. Treosulfan was generally well-tolerated despite comorbidities and heavy pre-treatment. Our study demonstrates that patients' preference did not influence prognosis negatively and remains important in gynaecologic oncology decision practice.</p><p><strong>Eudract nr: </strong>2004-000719-25; NCT 00170690.</p>","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2017-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0040-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34806179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana.","authors":"Dorcas Obiri-Yeboah,&nbsp;Yaw Adu-Sarkodie,&nbsp;Florencia Djigma,&nbsp;Kafui Akakpo,&nbsp;Ebenezer Aniakwa-Bonsu,&nbsp;Daniel Amoako-Sakyi,&nbsp;Simpore Jacques,&nbsp;Philippe Mayaud","doi":"10.1186/s40661-017-0041-1","DOIUrl":"https://doi.org/10.1186/s40661-017-0041-1","url":null,"abstract":"<p><strong>Background: </strong>Modern cervical cancer screening increasingly relies on the use of molecular techniques detecting high-risk oncogenic human papillomavirus (hr-HPV). A major challenge for developing countries like Ghana has been the unavailability and costs of HPV DNA-based testing. This study compares the performance of <i>care</i>HPV, a semi-rapid and affordable qualitative detection assay for 14 hr-HPV genotypes, with HPV genotyping, for the detection of cytological cervical squamous intraepithelial lesions (SIL).</p><p><strong>Methods: </strong>A study comparing between frequency matched HIV-1 seropositive and HIV-seronegative women was conducted in the Cape Coast Teaching Hospital, Ghana. A systematic sampling method was used to select women attending clinics in the hospital. Cervical samples were tested for HPV by <i>care</i>HPV and Anyplex-II HPV28 genotyping assay, and by conventional cytology.</p><p><strong>Results: </strong>A total of 175 paired results (94 from HIV-1 seropositive and 81 from HIV-seronegative women) were analyzed based on the ability of both tests to detect the 14 hr-HPV types included in the <i>care</i>HPV assay. The inter-assay concordance was 94.3% (95%CI: 89.7-97.2%, kappa = 0.88), similar by HIV serostatus. The <i>care</i>HPV assay was equally sensitive among HIV-1 seropositive and seronegative women (97.3% vs. 95.7%, <i>p</i> = 0.50) and slightly more specific among HIV-seronegative women (85.0% vs. 93.1%, <i>p</i> = 0.10). <i>care</i>HPV had good sensitivity (87.5%) but low specificity (52.1%) for the detection of low SIL or greater lesions, but its performance was superior to genotyping (87.5 and 38.8%, respectively). Reproducibility of <i>care</i>HPV, tested on 97 samples by the same individual was 82.5% (95%CI: 73.4-89.4%).</p><p><strong>Conclusions: </strong>The performance characteristics of <i>care</i>HPV compared to genotyping suggest that this simpler and cheaper HPV detection assay could offer a suitable alternative for HPV screening in Ghana.</p>","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2017-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0041-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34792012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.","authors":"Melissa K Frey,&nbsp;Bhavana Pothuri","doi":"10.1186/s40661-017-0039-8","DOIUrl":"https://doi.org/10.1186/s40661-017-0039-8","url":null,"abstract":"<p><p>Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations in the <i>BRCA1/2</i> genes. However, through germline and tumor sequencing an understanding of the larger phenomenon of homologous recombination deficiency (HRD) has emerged. HRD impairs normal DNA damage repair which results in loss or duplication of chromosomal regions, termed genomic loss of heterozygosity (LOH). The list of inherited mutations associated with ovarian cancer continues to grow with the literature currently suggesting that up to one in four cases will have germline mutations, the majority of which result in HRD. Furthermore, an additional 5-7% of ovarian cancer cases will have somatic HRD. In the near future, patients with germline or somatic HRD will likely be candidates for a growing list of targeted therapies in addition to poly (ADP-ribose) polymerase (PARP) inhibitors, and, as a result, establishing an infrastructure for widespread HRD testing is imperative. The objective of this review article is to focus on the current germline and somatic contributors to ovarian cancer and the state of both germline and somatic HRD testing. For now, germline and somatic tumor testing provide important and non-overlapping clinical information. We will explore a proposed testing strategy using somatic tumor testing as an initial triage whereby those patients found with somatic testing to have HRD gene mutations are referred to genetics to determine if the mutation is germline. This strategy allows for rapid access to genomic information that can guide targeted treatment decisions and reduce the burden on genetic counselors, an often limited resource, who will only see patients with a positive somatic triage test.</p>","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2017-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0039-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34776254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report","authors":"S. Paraghamian, T. Longoria, R. Eskander","doi":"10.1186/s40661-017-0038-9","DOIUrl":"https://doi.org/10.1186/s40661-017-0038-9","url":null,"abstract":"","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0038-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43152950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and treatment of vulvar Merkel cell carcinoma: a systematic review","authors":"A. Nguyen, Ahmed Tahseen, Adam M. Vaudreuil, G. Caponetti, C. Huerter","doi":"10.1186/s40661-017-0037-x","DOIUrl":"https://doi.org/10.1186/s40661-017-0037-x","url":null,"abstract":"","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-017-0037-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41698785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in the surgical staging of high-grade endometrial cancer in the United States","authors":"J. Foote, S. Gaillard, G. Broadwater, J. Sosa, B. Davidson, M. Adam, A. Secord, M. Jones, J. Chino, L. Havrilesky","doi":"10.1186/s40661-016-0036-3","DOIUrl":"https://doi.org/10.1186/s40661-016-0036-3","url":null,"abstract":"","PeriodicalId":91487,"journal":{"name":"Gynecologic oncology research and practice","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40661-016-0036-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46869555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}